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Objectives. We examined the time course of ventricular func- 
tional improvement in patients with dilated cardiomyopathy who 
received beta-blockade and the long-term effects of beta-blockade 
on ventricular mass and geometry in these patients. 
Background. Previous studies have shown that beta-adrenergic 
blocking agents when administered long term improve ventricular 
function in patients with heart failure. However, the time course of 
improvement in ventricnlar function and the long-term effects of 
beta-blockade on ventricular mass and geometry are not known. 
Methods. Twen~-six men with dilated cardiomyopathy under- 
went serial echocardiography on days 0 and 1 and months 1 and 
3 of either metoprolol (n = 16) or standard therapy (n = 10). At 
3 months all patients on standard therapy were crossed over to 
metoprolol, and late echocardiograms were obtained after 18 -+ 5 
(mean _+ SD) months of metoprolol therapy. All echocardiograms 
were read in blinded manner. 
Results. Patients treated with metoprolol had an initial decline 
(day 1 vs. day 0) in ventricular function (increase in end-systolic 
volume and decrease in ejection fraction). Ventricular function 
improved between months 1 and 3 (p = 0.013, metoprolol vs. 
standard therapy). Left ventricular mass regressed at 18 months 
(333 -+ 85 to 275 -+ 53 g, p = 0.011) but not at 3 months. Left 
ventricular shape became less spherical and assumed a more 
normal elliptical shape by 18 months (major/minor axis ratio 
1.5 -+ 0.2 to 1.7 -+ 0.2, p = 0.0001). 
Conclusions. Patients with heart failure treated with metopro- 
lol do not demonstrate an improvement in systolic performance 
until after 1 month of therapy and may have a mild reduction in 
function initially. Long-term therapy with metoprolol results in a 
reversal of maladaptive remodeling with reduction in left ventric- 
ular volumes, regression of left ventricular mass and improved 
ventricular geometry by 18 months. 
(J Am Coll Cardiol 1995;25:1154-61) 
Modern therapy for congestive heart failure has focused not only 
on reversing hemodynamic abnormalities, uch as elevated intra- 
cardiac pressures and decreased cardiac output, but also on 
counteracting the effects of compensatory neurohormonal activa- 
tion (1,2). These neurohormonal mechanisms result in short-term 
hemodynamic support, but in the long term they appear to 
augment he progression of heart failure and may precipitate 
cardiovascular death (2). Thus, angiotensin-converting enzyme 
inhibitors, which counteract the effects of the renin-angiotensin 
system, have been shown to confer a survival benefit in patients 
with congestive heart failure (3). 
The sympathetic nervous ystem is another neurobormonal 
pathway that has become the recent focus for treatment of 
congestive heart failure using beta-adrenergic blocking agents 
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(1). Our laboratory (4,5) and others (1,6-10) have shown 
improved ventricular function in patients with heart failure 
treated with long-term beta-adrenergic blockade. Yet at least 
two short-term (<1 month) studies (11,12) reported no im- 
provement with this therapy. It has been observed that many 
patients report transient worsening of their symptoms on 
initiation of beta-blocker therapy. Therefore, this study was 
performed to evaluate the time course of improvement in 
ventricular function in patients receiving metoprolol. We hy- 
pothesized that the negative inotropic effects of metoprolol 
would result in initial worsening of left ventricular function 
with a subsequent improvement in ejection fraction and vol- 
umes after long-term therapy. Metoprolol was chosen because 
it was the most widely studied beta-blocker for congestive 
heart failure when this study was initiated (1). 
We also wanted to determine whether beta-adrenergic 
blockade affects left ventricular mass and geometry. An in- 
crease in left ventricular mass, often found in patients with 
heart failure, has been associated with an increased risk of 
cardiovascular events and a higher mortality rate (13,14). The 
failing heart also undergoes progressive changes in size and 
shape as well as mass (15). These changes result in a more 
spherical or globular ventricular geometry that may produce an 
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increase in meridional wall stress (15), abnormal distribution 
of fiber shortening (15) and an increase in functional mitral 
regurgitation (16) and may be associated with worsened exer- 
cise tolerance (17) and poorer long-term survival (18). There- 
fore, we also analyzed the effects of long-term beta-blockade 
on left ventricular mass and geometry. We hypothesized that 
long-term metoprolol therapy would exert favorable ffects on 
wall mass and produce a more elliptical (normal) geometry. 
Methods 
Patient recruitment. Between December 1, 1990 and Au- 
gust 30, 1993, 26 men (mean [+1 SD] age 53 _+ 11 years, range 
35 to 78) with congestive heart failure underwent serial 
echocardiography at the Dallas Veterans Administration Med- 
ical Center. All patients had an ejection fractions <0.45 before 
entry into the study and were in New York Heart Association 
functional classes II to IV. 
Study patients were recruited from two sources: 1) 16 
patients with nonischemic dilated cardiomyopathy who were 
part of a randomized double-blind invasive study of metoprolol 
(5) and who also participated in this study were randomized to
receive metoprolol (n = 10) or placebo (n -- 6); 2) 10 patients 
with heart failure of any etiology (5 with ischemic ardiomy- 
opathy and 5 with nonischemic dilated cardiomyopathy) were 
recruited for either open-label administration f metoprolol 
(n = 6) or continuation of their current therapy without 
initiation of beta-blockers (n = 4). The "standard therapy" 
group consisted of those patients either andomized toreceive 
placebo r continue on current therapy without beta-blockade. 
Patients were excluded for any of the following: severe renal 
disease (creatinine >2.5 mg/dl), hepatic disease (serum gluta- 
mate oxaloacetate transaminase or serum glutamate pyruvate 
transaminase >3 times normal), pulmonary disease (reactive 
airway disease), rheumatologic disease (systemic lupus ery- 
thematosus, polyarteritis nodosa, scleroderma or dermatomy- 
osiris) or endocrine disease (primary aldosteronism, pheochro- 
mocytoma or hyperthyroidism and hypothyroidism). Patients 
with recent myocardial infarction (<3 years before entry) or 
constrictive, restrictive, hypertrophic or primary valvular dis- 
ease were excluded, as were patients with a recent (<3 
months) history of ethanol abuse. Patients with technically 
difficult echocardiograms were also excluded. 
All medications were allowed except beta-adrenergic blockers 
within 3 months of the study. All patients (except two who were 
receiving isosorbide dinitrate/hydralazine) hadbeen on long-term 
angiotensin-converting enzyme inhibitor therapy before the start 
of the study, and the dose was not changed for the duration of the 
study. All other cardiac medication dosages remained constant 
during the study, with the exception of diuretic drugs, which were 
changed as clinically indicated. After 3 months of placebo ther- 
apy, patients from the randomized sample were crossed over to 
metoprolol for long-term therapy. 
Twenty patients underwent echocardiography just before 
and at 18 + 5 months (range 10.5 to 27.0) after initiation of 
metoprolol therapy to assess long term effects of metoprolol n 
left ventricular mass and geometry. 
Written informed consent was obtained from each patient, 
and the protocol was approved by the Human Studies Subcom- 
mittee of the Dallas Veterans Administration and University of 
Texas Southwestern Medical Centers in November 1990. 
Metoprolol titration. The study drug therapy was initiated 
after initial echocardiography in all patients. The drug was 
titrated weekly at the following doses: 6.25, 12.5, 25 and 50 mg 
twice daily. All patients tolerated the full dosage by 1 month. 
Echocardiography. All patients underwent two-dimensional 
transthoracic e hocardiography in the left lateral decubitus posi- 
tion (Vingmed CFM 750 instrument with a 3.25-MHz transduc- 
er). By phantom calibration, this transducer has an axial and 
lateral resolution of 1 and 3 ram, respectively. Measurement of
vertical distance using the Vingmed analysis oftware was also 
evaluated by phantom and was highly accurate, with a 2% 
coefficient of variation. Gain settings were adjusted to optimize 
visualization of the left ventricular endocardial contours while 
avoiding excessive gain artifact. Images were obtained from 
standard echocardiographic parasternal long- and short-axis views 
at the midventricular level and apical four- and apical two- 
chamber views. All images were recorded on Vz-in. VHS tape and 
were subsequently analyzed in a blinded manner by an echocar- 
diographer who had no knowledge of either the study medication 
or the time of evaluation. Left ventricular septal and posterior 
wall thicknesses at end-diastole were measured from the paraster- 
hal long-axis view at the tips of the mitral eaflets according to the 
recommendations f the American Society of Echocardiography 
(19). Two-dimensional echocardiographic estimation of left ven- 
tricular mass was performed using the 5/6 area-length method 
(19). Accordingly, the areas encompassed bythe left ventricular 
epicardial and endocardial borders were traced at end-diastole 
from the parasternal short-axis view at the midventricular level. 
Left ventricular length (L) at end-diastole was measured from the 
apical four-chamber view. Myocardial thickness (t) was calculated 
from the areas of the epicardial (A1) and endocardial (A2) 
contours according to the following formula (19): 
t = \/AJ~"- \iA~j~r. 
Left ventricular mass (LVM) was then calculated as follows 
(19): 
LVM = 1.05 {[5/6AI(L + t)] - [5/6A2(L)]}. 
Left ventricular geometry was assessed by a major/minor 
axis ratio at end-diastole (16). As this ratio approaches 1,the 
ventricle becomes more spherical. As this ratio increases, the 
ventricle becomes more elliptical. 
Intraobserver and interobserver variability of our echocar- 
diographic measurements (volumes and mass) has been tested 
by repeated analysis of 20 echocardiograms from patients with 
heart failure. The standard error of the estimate for intraob- 
server measurements was 23 ml for volumes (r = 0.97, y = 
0.919x + 7.5, p = 0.0001) and 28 g for mass (r = 0.90, y = 
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Table 1. Baseline Clinical Characteristics of Patients With Standard Therapy Only Versus Those With 
Metoprolol Plus Standard Therapy 
Standard Therapy Metoprolol 
(n -  10) (n -  16) p Value 
Age (yr) 56 _+ 3 52 _+ 3 0.35 
Body surface area (m 2) 1.87 + 0.04 2.0l _+ 0.05 0.054 
Isch/NIDC 3/'7 2/14 0.55 
Black/white 6/'4 8/8 0.93 
Alcohol abuse (yes/no) 5/5 6/10 0.83 
LVEF 0.24 -+ 0.03 0.23 +_ 0.02 0.82 
LVEDV (ml) 288 -+ 24 256 + 22 0.36 
LVESV (ml) 219 _+ 21 196 -+ 16 0.39 
LVSV (ml) 69 + 10 61 -+ 8 0.52 
LVM (g) 315 + 31 338 +- 21 0.54 
Major axis (cm) 9.7 + 11.2 9.3 + 0.3 0.35 
Minor axis (cm) 6.3 -+ 0.3 6.0 _+ 0.2 0.50 
Sphericity. index 1.6 _+ 0.1 1.6 -+ 0.1 0.93 
Data presented are mean values : 1 SEE or number of patients. Isch = ischemic etiology for heart failure; LVEDV 
(LVESV) - left ventricular end-diastolic (end-systolic) volume; LVEF = left ventricular ejection fraction; LVM - left 
ventricular mass; LVSV - left vcntricular stroke volume; NIDC nonischcmic dilated cardiomyopathy. 
0.796x + 71, p = 0.0001). The standard error of the estimate 
for interobserver measurements was 25 ml for volumes (r = 
0.93, y = 0.947x+ 19, p = 0.0001) and 27 g for mass (r = 0.91, 
y = 0.742x + 93, p = 0.0001). 
Statistical analysis. Nominal variables were compared by a 
chi-square contingency table analysis. Changes in left ventric- 
ular function as reflected by ejection fraction, end-diastolic and 
end-systolic volumes were compared by repeated-measures 
analysis of variance (ANOVA). Because three metoprolol 
group patients missed one echocardiographic assessment ( he 
1-month evaluation in all patients), and one in the placebo 
group missed one evaluation (at 3 months), the data were 
assessed with BMDP subprogram 5V to perform unbalanced 
repeated-measures ANOVA using maximal likelihood tech- 
niques. When the repeated-measures ANOVA demonstrated 
a nominal interaction, within-group differences were tested by 
a Student paired t test with Bonferroni correction. For within- 
group comparisons, a trend was defined by p < 0.05 and 
statistical significance by a more conservative p = 0.008. 
For assessment of long-term (18 month) changes due to 
beta-blockers (volumes, ejection fraction, mass and geometry), 
we used a Student paired t test. For the patients who were 
originally randomized to receive placebo and were then 
crossed over to metoprolol therapy at 3 months, the results 
from the 3-month echocardiogram were used as the baseline 
value. Results are expressed as mean value _+ 1 SD, unless 
otherwise specified, and p < 0.05 was considered significant. 
Resu l ts  
Time course of ventricular functional improvement. Base- 
fine characteristics. The standard therapy and metoprolol 
groups were well matched with regard to age, race and etiology 
of heart failure (Table 1). Although the metoprolol group 
patients had a slightly greater body surface area, indexed 
volumes were not significantly different between groups. Five 
patients in the standard therapy group and six in the metopro- 
lol group had some history of alcohol abuse; however all but 
one patient (standard therapy group) had quit >6 months 
before study entry. 
Table 2 and Figure 1 demonstrate changes in end-diastolic 
and end-systolic volumes and ejection fraction for the two 
Table 2. Mean (_+SD) Changes in Volumetric and Ejection Fraction Indexes Over Time 
Baseline Day 1 Month 1 Month 3 
p Value 
Over Time Versus Standard Therapy 
Metoprolol group (n 16) 
LVEDV (ml) 256 _+ 88 273 -- 84 268 _+ 87 243 _+ 88 
LVESV (ml) 196 _+ 66 217 + 68* 206 + 74 170 _+ 81 
LVEF 0.23 _+ 0.07 0.21 + 0.07t 0.24 +/).08 0.32 _+ 0.10' 
Standard therapy group (n - 10) 
LVEDV (ml) 288 _+ 76 300 _+ 64 309 _+ 55 262 +_ 69:[: 
LVESV (ml) 219 + 65 225 _+ 57 232 _+ 55 204 _+ 68 
LVEF 0.24 _+ 0.08 0.25 +_ 0.08 0.25 + 0.09 0.25 _+ 0.08 
0.19 
0.0017 
0.0001 
0.0032 
0.16 
0.93 
0.80l 
0.072 
0.013 
* p < 0.0001, t p < 0.05 versus baseline. :~ p < 0.02 versus day l and month 1. Abbreviations as in Table 1. 
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Figure 1. Changes in left ventricular ejection fraction from 
baseline to day 1, month 1 and month 3in the metoprolol and 
standard therapy groups. Ejection fraction decreased at day 1 
and increased only after 1 month of metoprolol therapy. Inthe 
placebo group, ejection fraction did not change significantly. 
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groups at baseline and at day 1 and months 1 and 3 of drug 
therapy. There were no significant differences between the 
standard therapy and metoprolol groups at baseline. In the 
metoprolol group there was an increase in end-systolic volume 
(p < 0.0001) and a trend toward an increase in end-diastolic 
volume (p = 0.018) at day 1. Left vcntricular ejection fraction 
at day 1 was depressed (p = 0.021) but returned to baseline by 
month 1 and improved between months 1 and 3. By 3 months 
of therapy there was a significant increase in left ventricular 
ejection fraction in the metoprolol group patients compared 
with those in the standard therapy group (p -- 0.0001 for 
metoprolol therapy at 3 months vs. baseline; p = 0.013 for 
metoprolol vs. standard therapy). This improvement in left 
ventricular ejection fraction was due primarily to a late de- 
crease in end-systolic volume. End-diastolic and end-systolic 
volumes in the standard therapy group increased nonsignifi- 
candy at day 1 and month 1 but returned to baseline by month 
3. There was no change in left ventricular ejection fraction in 
the standard therapy group (p = 0.63 for standard therapy at 
3 months vs. baseline). 
Long-term (18 month) effects of metoprolol on ventrieular 
size, shape and mass. Long-term changes in heart rate, sys- 
tolic blood pressure and left ventricular volume, ejection 
fraction, mass and geometry are presented in Table 3. Meto- 
prolol therapy reduced heart rate (88 _+ 13 vs. 74 _+ 11 
beats/rain, p = 0.0006) and increased systolic blood pressure 
(117 _+ 26 vs. 129 _+ 22 mm Hg, p = 0.022) by 18 months of 
therapy (vs. baseline). Left ventricular end-diastolic volume 
(247 _+ 76 vs. 186 + 48 ml, p = 0.0067) and end-systolic volume 
(188 _+ 57 vs. 111 _+ 44, p = 0.0006) decreased with long-term 
metoprolol therapy, and left ventricular ejection fraction 
(0.24 _+ 0.07 vs. 0.41 _+ 0.13, p = 0.0002) continued to improve 
from baseline at late echocardiography. 
In 14 patients who took metoprolol from the start of the 
study, the 18-month follow-up echocardiogram showed no 
change in baseline left ventricular mass and that after 3 months 
of therapy (327 _+ 79 vs. 327 _+ 76, respectively, p = NS); 
however, by 18 months of metoprolol therapy, left ventricular 
mass had regressed significantly (269 _+ 57 g, p = 0.029). In 
addition, when all patients were considered, including those 
who crossed over to metoprolol therapy (n = 20), left ventric- 
ular mass had regressed by 18 months (333 _+ 85 vs. 275 + 53 g, 
p = 0.011). 
In 14 patients who took metoprolol from the start of the 
study, the 18-month follow-up echocardiogram showed no 
change between baseline left ventricular geometry (as manifest 
by major/minor axis ratio at end-diastole) and that after 3 
months of therapy (1.6 _+ 0.2 vs. 1.6 _+ 0.2, respectively, p = 
0.63); however, by 18 months of metoprolol therapy, the left 
ventricle had undergone remodeling and had become less 
spherical and more elliptical (1.8 _+ 0.2, p = 0.01). The 
standard therapy group also had no change in left ventricular 
geometry (1.6 + 0.2 to 1.4 + 0.2, p = 0.092 vs. baseline; p = 
0.095 vs. metoprolol). In addition, when all patients were 
considered, including those who were crossed over to meto- 
prolol therapy (n = 20), left ventricular geometry had im- 
proved by 18 months (1.5 _+ 0.2 to 1.7 + 0.2, p = 0.0001). 
Discuss ion  
The present study demonstrates that long-term metoprolol 
therapy for dilated cardiomyopathy leads to time-dependent 
improvement i  left ventricular volumes and ejection fraction, 
regression of left ventricular hypertrophy and restoration of 
elliptical eft ventricular geometry. The reduction in ventricu- 
lar volumes does not occur within the first month of beta- 
blocker therapy. In fact, there was a trend toward larger 
volumes and reduced ejection fraction on initiation of meto- 
prolol therapy. However, beta-adrenergic blockade improved 
left ventricular function, as evidenced by an increase in left 
ventricular ejection fraction by 3 months of therapy. Thus, it is 
not surprising that the only two studies of beta-blockade in 
heart failure that failed to show improvement in left ventricu- 
lar performance or lessening of symptoms (11,12) were both 
< 1 month in duration. These data reflect he clinical observa- 
tion that some patients report worsening of symptoms (short- 
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Table 3. Long-Term (18 mo) Effects of Metoprolol n Ventricular Size, Shape and Mass 
(mean + SD) 
Baseline 3 mo 18 mo p Value 
Patients Initially Taking Metoprolol (n 14) 
Heart rate (beats/rain) 91 + 13 81 + 14 78 = 13 0.012 
Systolic BP (ram Hg) 122 _+ 27 125 _+ 21 134 _+ 21 0.067 
EDV (ml) 252 + 83 237 _+ 78 177 + 36 0.0039 
ESV (ml) 192 + 60 162 + 73 100 -- 36 0.0005 
EF 0.24 + 0.08 0.33 _+ 0.10 0.44 _+ 0.13 0.0004 
LVM (g) 327 _+ 79 327 _+ 76 269 _+ 57 0.029 
Sphericity 1.6 + 0.2 1.6 + 0.2 1.8 -+ 0.2 0.01 
Patients Initially Taking Standard Therapy (n 10) 
Heart rate (beats/rain) 87 -+ 12 86 -+ 13 0.84 
Systolic BP (mm Hg) 110 -+ 16 109 _+ 17 0.84 
EDV (ml) 288 ± 76 263 -+ 69 0.14 
ESV (ml) 219 _+ 65 204 _+ 68 0.083 
EF 0.24 -+ 0.08 0.25 + 0.08 0.50 
LVM (g) 303 -+ 95 318 -+ 98 0.41 
Sphericity 1.6 -* 0.2 1.4 -+ 0.2 0.092 
All Patients Studied at 18 mo of Metoprolol Therapy (n = 20) 
Heart rate (beats/rain) 88 = 13 74 + l l  0.0006 
Systolic BP (ram Hg) 117 + 26 129 -+ 22 0.022 
EDV (ml) 247 + 76 186 -+ 48 0.0067 
ESV (ml) 188 + 57 111 _+ 44 0.0006 
EF 0.24 -+ 0.07 0.41 _+ 0.13 0.0002 
LVM (g) 333 -+ 85 275 + 53 0.01I 
Sphericity 1.5 -+ 0.2 1.7 + 0.2 0.0001 
BP = blood pressurc; sphericity - majoffminor axis ratio (see text); other abbreviations a in Table 1. 
ness of breath and edema) in the first few weeks of beta- 
blocker titration. Previous trials (5,20) have shown that left 
ventricular function continues to improve even beyond 3 
months of therapy. To our knowledge, our study is the first to 
demonstrate hat this continued improvement is associated 
with regression of hypertrophy and favorable left ventricular 
remodeling at 18 months. 
The mechanism by which beta-adrenergic blockade im- 
proves left ventricular systolic function is not yet clear. For 
many years the predominant theory was based on the obser- 
vation that betal-cell surface receptors are downregulated in 
heart failure (6,21,22). This downregulation probably occurs as 
a protective mechanism against the long-term sympathetic 
stimulation and its possible toxic effects (22,23). Upregulation 
of these receptors and renewed responsiveness to beta-agonist 
stimulation have been demonstrated after beta-blockade with 
metoprolol (6). However, although upregulation may play a 
role in exercise and stress responsiveness (23) it cannot explain 
the improvement in rest left ventricular function, for several 
reasons. First, if improved left ventricular systolic function is to 
be attributed to an increased sensitivity to sympathetic stimu- 
lation, heart rate should increase along with the increased 
contractility (1,4,5,10). Instead, heart rate decreases with beta- 
blocker therapy. Second, if improved function is to be attrib- 
uted to an increase in beta-receptor density, a direct relation 
between receptor density and systolic function should exist. 
However, beta-receptor density increases rapidly within a few 
days of beta-blockade, but, as shown in the present study, left 
ventricular function does not improve significantly until after 1 
month of therapy (1,23). Finally, some beta-blocking agents 
have been shown to improve left ventricular function without 
receptor upregulation (23,24). Thus, other secondary mecha- 
nisms must be at work, including alterations in myocardial 
metabolism (1,5), inhibitory actions on the renin-angiotensin 
system (1), inhibition of endothelin and cytokine release 
(1,25), improved calcium transport within the myocyte (26) or 
cellular effects on protein synthesis, message xpression and 
function of the mitochondria or sarcoplasmic reticulum. 
Thus, the initial mild depression of ventricular function may 
be due to the negative inotropic properties of beta-receptor 
blockade. During initial titration to larger doses, the left 
ventricle may actually be more depressed, although we did not 
perform echocardiography at 1 to 2 weeks of therapy to 
examine this. Secondary effects of beta-adrenergic blocking 
agents may then occur after a few weeks of therapy. These 
secondary effects, which probably represent healing and im- 
provement in myocyte function, begin to offset the negative 
inotropic effect of beta-receptor blockade, making the heart 
more efficient and improving its contractility and relaxation. 
Further esearch will help to elucidate these secondary mech- 
anisms of action of beta-blockade inpatients with heart failure. 
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Effect ofmetoprolol on left ventricular mass. The results of 
the present study demonstrate hat long-term therapy with the 
beta-antagonist metoprolol results in regression of left ventric- 
ular hypertrophy. In previous tudies left ventricular hypertro- 
phy has been shown to be an independent risk factor for 
cardiovascular events and increased mortality (13,14). Left 
ventricular hypertrophy also is associated with decreased cor- 
onary flow reserve (27), decreased subendocardial perfusion 
(27), reduced coronary flow/g of tissue (28) and increased 
myocardial oxygen consumption (29), factors that may favor 
the development of myocardial ischemia. Thus, it is attractive 
to speculate that regression of hypertrophy might reduce 
cardiovascular risk and ischemia (30). 
Key factors producing myocardial hypertrophy include 
pressure or volume overload and myocardial stimulation by 
angiotensin II, which acts through such local growth factors as 
transforming rowth factor-beta to produce growth (31-35). 
Endothelin also has been postulated to have a possible role in 
promoting ventricular hypertrophy (32,33). Some vasodilator 
agents (hydralazine or hydralazine plus isosorbide dinitratc) 
have been shown to reduce load and regress hypertrophy in 
patients with idiopathic dilated cardiomyopathy (36). In addi- 
tion, angiotensin-converting enzyme inhibitors have been 
shown to regress hypertrophy in spontaneously h pertensive 
rats (31,37) and in humans (33). 
The role of the adrenergic nervous ystem in the develop- 
ment of left ventricular hypertrophy is less well defined (33). 
Some evidence suggests a role for the adrenergic nervous 
system in the development of hypertrophy: 1) Norepinephrine 
has been shown in vitro to stimulate protein synthesis and 
hypertrophy (38); 2) long-term norepinephrine administration 
induces left ventricular hypertrophy in dogs (39); 3) heart 
weight/body weight has been shown to be proportional to 
myocardial catecholamine concentrations in spontaneously 
hypertensive rats (40); and 4) left ventricular hypertrophy has 
been associated with a reduced inotropic response to catechol- 
amine levels (41), suggesting possible beta-receptor downregu- 
lation or uncoupling, a long-term response to norepinephrinc 
(21-23). Despite these data, it is not clear that norepinephrine 
is a major contributor to the development of hypertrophy in
humans. It is also unclear whether the regression of hypertro- 
phy seen in this study was a primary effect of adrenergic 
blockade or was due to an indirect effect of the therapy. The 
response to beta-blockade in patients with hypertrophy due to 
hypertension has been variable despite reductions in blood 
pressure (40,42). Thus, indirect effects, such as inhibition 
of renin-angiotensin (1,32,43), inhibition of cytokine and 
endothelin release (25,32,33), production of bradykinin (43) or 
reduction in left ventricular wall stress (1,4,5,10,34,35,44), may 
have played a role in reducing left ventricular mass in our study 
patients. Indeed, the reduction in volumes by 3 months of 
therapy preceded the reduction in mass seen at 18 months. 
This suggests that reduction in wall stress may play some role 
in reducing mass. Finally, recent studies have elucidated a
biochemical pathway connecting changes in cyclic adenosine 
monophosphate, the second messenger for beta-adrenergic 
stimulation, to changes in the ms oncogene mitogen-activated 
protein (RAS-MAP) kinase system, which stimulates everal 
proto-oncogenes. This is an attractive additional theoretic 
mechanism by which beta-adrenergic blockade could result in 
alterations in left ventricular mass (45,46). The importance of 
regression of hypertrophy in these patients with regard to 
morbidity and mortality and the mechanism by which this 
occurs deserve further investigation. 
Effect of metoprolol on left ventricular geometry. Previous 
investigators (15,37) have shown that the left ventricle under- 
goes global changes in size, shape and mass after myocardial 
infarction, a process known as remodeling. Noninfarcted fail- 
ing myocardium undergoes imilar time-dependent changes 
(15,18) that have been attributed to side-to-side slippage, 
increased myocyte length and hypertrophy (15). The result is a 
shift in left ventricular geometry from a prolate ellipse to a 
more spherical shape. A spherical ventricle xhibits increased 
meridional wall stress (15), abnormal distribution of fiber 
shortening (15), functional mitral regurgitation (16), lessened 
exercise tolerance (17) and poorer long-term survival (18). 
Angiotensin-converting enzyme inhibitors have been shown 
to slow ventricular enlargement and remodeling after myocar- 
dial infarction (15,17,37) and chronic heart failure (47). The 
present study demonstrates that the addition of long-term 
beta-blockade with metoprolol to background therapy with 
angiotensin-converting enzyme inhibitors confers additional 
benefit by reducing left ventricular volumes and restoring a 
more normal ventricular geometry. Thus, the present study 
suggests that beta-blocking agents may not simply slow remod- 
eling, but may actually produce a reversal of maladaptive 
remodeling, or "reverse remodeling." 
Study limitations. Although the first 16 patients entered 
into this study were randomized in a placebo-controlled, 
double-blind manner, the remaining 10 patients were not 
randomized in a similar way. Thus this study is not a random- 
ized investigation. However, the echocardiograms were inter- 
preted in a blinded manner with regard to study medication 
and time of echocardiography. In addition, the 18-month data 
were not controlled as patients were crossed over to active 
drug after 3 months. There was therefore no placebo group for 
intergroup comparison at 18 months. 
We used two-dimensional echocardiography to assess wall 
mass and volumes. Although this methodology is standard 
(19,48), use of three-dimensional echocardiography (49,50) or 
magnetic resonance imaging (51) may be more accurate. 
However, any errors in measurement would be random, so the 
use of two-dimensional echocardiography cannot account for 
statistically significant changes in left ventricular mass and 
dimensions. 
Because five patients in the standard therapy group and six 
in the metoprolol group had some history of alcohol abuse, it 
is possible that previous use may have influenced long-term 
changes. However, this is unlikely because the standard ther- 
apy group showed no changes in left ventricular mass, geom- 
etry or volumes at 3 months after entry (i.e., at least 6 months 
since previous alcohol use). All of the metoprolol group 
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patients had ceased alcohol use at least 6 months before study 
entry, and most had quit years before entry. These data suggest 
that alcohol use is probably not a significant factor. 
Conclusions. Long-term therapy of dilated cardiomyopa- 
thy with beta-adrenergic blockade results in time-dependent 
improvement in left ventricular ejection fraction, hypertrophy 
and geometry. Left ventricular volumes and ejection fraction 
may worsen after initiation of metoprolol but show improve- 
ment by 3 months. Regression of left ventricular hypertrophy 
and restoration of ventricular geometry are apparent by 18 
months, suggesting that reverse remodeling of the failing left 
ventricle is possible. Further studies are needed to define the 
mechanism by which these favorable changes occur. 
We acknowledge the technical assistance of Barbara Hatfield, RN and Arvella 
Peters, University of Texas Southwestern a d Dallas Veterans Administration 
Medical Centers, Dallas, Texas. 
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